A better molecular understanding of Akt isoform effectors mediating insulin metabolic control holds the promise for the development of new and specific pharmacological interventions to improve insulin action in conditions characterized by defective Akt signalling, like insulin resistance and type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.